Akorn, Inc. (NASDAQ:AKRX) has been given a consensus recommendation of “Hold” by the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and eight have given a hold recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $29.17.
Several analysts recently issued reports on the company. Zacks Investment Research cut Akorn from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub cut Akorn from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 20th. Piper Jaffray Companies set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 22nd. Finally, Jefferies Group set a $34.00 target price on Akorn and gave the stock a “hold” rating in a research note on Sunday, October 29th.
In other Akorn news, major shareholder John N. Kapoor sold 13,629 shares of the firm’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $32.67, for a total value of $445,259.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian Tambi sold 15,100 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total transaction of $503,585.00. The disclosure for this sale can be found here. Company insiders own 28.20% of the company’s stock.
Shares of Akorn (AKRX) opened at $32.33 on Friday. The company has a quick ratio of 3.17, a current ratio of 4.16 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $4,040.00, a PE ratio of 54.80, a P/E/G ratio of 1.66 and a beta of 1.33. Akorn has a 12 month low of $19.15 and a 12 month high of $34.00.
ILLEGAL ACTIVITY NOTICE: “Akorn, Inc. (AKRX) Given Average Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/03/akorn-inc-akrx-given-average-recommendation-of-hold-by-analysts.html.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.